<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147955">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01858987</url>
  </required_header>
  <id_info>
    <org_study_id>NNR-08</org_study_id>
    <nct_id>NCT01858987</nct_id>
  </id_info>
  <brief_title>Stapler vs. LigaSure in Elective Hepatic Resection</brief_title>
  <acronym>CRUNSH II</acronym>
  <official_title>Stapler vs. LigaSure for Transection of the Parenchyma in Elective Hepatic Resection: CRUNSH II - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal technique of parenchymal transection in liver surgery has remained a matter of
      controversial debate among hepatobiliary surgeons. The optimal technique should enable
      secure sealing of the vascular and biliary structures that results in low intraoperative
      blood loss as well as low postoperative complication rates. Although numerous devices have
      been introduced and are used widely, high-level evidence, randomized controlled trials, that
      evaluate efficacy and safety of these devices are scarce. In the present randomized
      controlled trial two techniques of hepatic resection using vascular staplers and the
      LigaSure vessel sealing device are compared. While the primary endpoint is intraoperative
      blood loss a set of general and surgical variables will be analyzed to evaluate efficacy and
      safety of both methods.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intraoperative Blood loss</measure>
    <time_frame>Beginning to end of surgical procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Intraoperative blood loss represents the primary efficacy endpoint of the CRUNSH II-Trial. To obtain a more precise estimate for the individual patient patient's individual transection area will be considered as a continuous covariate in the analysis of covariance (ANOVA). The transection area will be assessed using an imprint of the resected specimen on a paper sheet with a known density of 80 mg/m2. The marked paper area will be cut and weight to calculate the transection area. Intraoperative blood loss will be measured according to the blood collected in the suction containers. Spilling water and ascites will be subtracted. Furthermore, swabs will be squeezed and their content will also be sucked and added to the fluid collected in the suction containers. Central venous pressure will be lowered below 5 cmH2O for the transection period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Liver Resection</condition>
  <arm_group>
    <arm_group_label>Stapler hepatectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liver resection using vascular stapler for transection of the parenchyma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LigaSure Hepatectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liver resection using LigaSure for transection of the parenchyma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stapler hepatectomy</intervention_name>
    <description>Liver resection using vascular stapler for transection of the parenchyma</description>
    <arm_group_label>Stapler hepatectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LigaSure hepatectomy</intervention_name>
    <description>Liver resection using LigaSure for transection of the parenchyma</description>
    <arm_group_label>LigaSure Hepatectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ligasure</intervention_name>
    <arm_group_label>LigaSure Hepatectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>vascular staple</intervention_name>
    <arm_group_label>Stapler hepatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective hepatic resection

          -  Parenchymal transection by vascular stapler and LigaSure feasible

          -  Age equal or greater than 18 years

          -  Informed consent

        Exclusion Criteria:

          -  Extrahepatic resection required based on preoperative imaging

          -  Participation in concurrent surgical intervention trials

          -  Expected lack of compliance

          -  Impaired mental state or language problems
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jurgen Weitz, MD</last_name>
    <email>Juergen.Weitz@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nuh Rahbari, MD</last_name>
    <email>nuh.rahbari@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UniversityHospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen Weitz, MD</last_name>
      <email>JÃ¼rgen Weitz &lt;Juergen.Weitz@uniklinikum-dresden.de&gt;</email>
    </contact>
    <contact_backup>
      <last_name>Nuh Rahbari, MD</last_name>
      <email>nuh.rahbari@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jurgen Weitz, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 20, 2013</lastchanged_date>
  <firstreceived_date>May 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Heidelberg</investigator_affiliation>
    <investigator_full_name>Nuh Rahbari</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
